CALR and neoplasm: Vaccination of mice with a DNA vaccine composed of HPV16 L2, E6, and E7 linked to calreticulin (CRT) was shown to induce E6- and E7-specific CD8+ T cells that conferred significant anti-tumor effects against E6/E7-expressing tumors and an L2-specific protective antibody response against HPV16 was demonstrated [126].